In patients with advanced (Stage III) HR+/HER2− breast cancer, mutations frequently occur in the phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway, accounting for up to 40% of mutations in this population [8]. This evidence concerns the gene AKT1 and breast carcinoma.